Drugs / Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
targets CCR5 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05470491 | Jan 2023 → Jul 2027 expected | HIV infectious disease, hematopoietic and lymphoid cell neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470491 ↗ |
| Action | Inhibit | “CCR5 receptor blocker” NCT05470491 ↗ |
| Route | Oral | “Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30” NCT05470491 ↗ |
| Target | CCR5 | “Maraviroc is used as GVHD prophylaxis, but not previously in combination with PTCy and bortezomib, and is additionally a CCR5 receptor blocker” NCT05470491 ↗ |